Annual accounts
Full accounts
30/09/2025Filing deadline
Made up to 31/12/2023Due 30/09/2025
- Next accounts made up to
- 31/12/2024
- Last accounts made up to
- 31/12/2023
GENEA BIOMEDX UK LIMITED
Active- 08314520Copy
Copy
Registry details
Reference data exactly as held at Companies House.
Copy registry details
- Registered office
- Office 20 Second Floor Innovation House, Ramsgate Road, Sandwich, Kent CT13 9FF
- Classification (SIC)
- Other research and experimental development on natural sciences and engineering (72.19 - SIC 2007)
- Accounts type
- Full
Company activity
The 4 most recent documents filed at Companies House.
Pre-Score for UK companies is coming soon
- 19/01/2026View PDF (22 pages)
Full accounts made up to 2023-12-31
- 08/01/2026View PDF (5 pages)
Confirmation statement made on 2025-11-30 with updates
- 13/12/2024View PDF (3 pages)
Confirmation statement made on 2024-11-30 with no updates
- 18/10/2024View PDF (1 pages)
Termination of appointment of Bo Liang as a director on 2024-10-18
Coming soon
What Pre-Score will tell you
- Whether the filed accounts are strengthening or weakening year on year.
- Whether this company files on time, and how often its record changes.
- How its officers and controlling parties connect to other UK companies.
Accounts and confirmation statement
The two filings Companies House requires every year, and where each one stands against its deadline today.
360 days overdue
Confirmation statement
Confirms the registry record is up to date
- Next statement date
- 30/11/2026
- Last statement dated
- 31/12/2023
Financial performance
The latest figures GENEA BIOMEDX UK LIMITED filed. Okredo holds filed accounts data for 2021–2023; the year-by-year record is on the financials page.
Net Assets
£-6.22M2023
28.79%vs 20222022: £-8.74M
Total Assets
£1.47M2023
-53.28%vs 20222022: £3.14M
Cash in Bank
£158.31K2023
-68.54%vs 20222022: £503.21K
Total Liabilities
£7.69M2023
-35.26%vs 20222022: £11.87M
Employees
52023
-3vs 20222022: 8
Of the 4 measures with an earlier filing to compare against, 1 rose and 3 fell. Total liabilities moved furthest, down 35.26% on 2022. See the full financial analysis for GENEA BIOMEDX UK LIMITED.
The full financial record
Four ways through GENEA BIOMEDX UK LIMITED's filed accounts — the year-by-year numbers, the compound rates and the ratios behind them.
Cash in Bank · -56.2% a year (CAGR)Three-year trend, 2021–2023Every measure end to end across 2021, 2022 and 2023, with the compound rate behind each one.See what moved5 chartsCharts by indicator5 filed indicators plotted year by year, 2021–2023.Plot the figuresNothing estimatedRatios from the filed figures5 ratios computed from this company's own reported amounts, each shown against the year it was derived from.Check the ratios5 × 3 yearsEvery figure by yearAll 5 measures Okredo tracks across 3 reported years, exactly as filed.Open the table
Employees
Headcount as reported to Companies House for 2021–2023.
| Year | Employees | Change |
|---|---|---|
| 2023 | 5 | -3 |
| 2022 | 8 | -3 |
| 2021 | 11 | – |
Reported employee count decreased from 11 in 2021 to 5 in 2023. See how headcount moved alongside the reported financials.
Credit report
It is a professional assessment of the company 's performance, revealing company's potential and risks, showing it's past experiences and revealing future prospects.
- Company potential
- Risk indicators
- Past performance
- Future prospects
Officers
10Directors, secretaries and other appointed officers, with the period each has served.
| Person | Role | Period | Connected companies |
|---|---|---|---|
| Director | 30/11/2012–30/09/2022 | 1 | |
| Director | 30/09/2022–21/06/2023 | 18 | |
| Director | 30/09/2022–21/06/2023 | 1 | |
| Director | 30/09/2022–21/06/2023 | 1 | |
| Director | 18/10/2024–Present | 1 | |
| Director | 30/09/2022–23/06/2023 | 3 | |
| Director | 30/11/2012–26/11/2015 | 1 | |
| Director | 01/12/2015–30/09/2022 | 0 | |
| Secretary | 11/02/2015–26/02/2016 | 0 | |
| Director | 22/06/2023–18/10/2024 | 0 |
Persons with significant control
6Individuals or entities with significant control over the company, as declared to Companies House.
| Person | Period | Connected companies |
|---|---|---|
| 01/07/2022–01/09/2022 | 0 | |
| 10/09/2018–27/12/2018 | 0 | |
| 30/11/2016–10/09/2018 | 0 | |
| 27/12/2018–01/07/2021 | 1 | |
| 01/09/2022–Present | 1 | |
| 21/06/2023–Present | 0 |
Filing history and recent activity
Every document on the Companies House record, newest first.
- Filings on record
- 20 Since 17/05/2017
- Last 12 months
- 2 -1 vs the year before
- Most recent filing
- 19/01/2026 8 months ago
What changed in the last year
- Accounts filedLatest 19/01/2026
- Confirmation statementLatest 08/01/2026
Filing timeline
- 19/01/2026View PDF (22 pages)
Full accounts made up to 2023-12-31
- 08/01/2026View PDF (5 pages)
Confirmation statement made on 2025-11-30 with updates
- 13/12/2024View PDF (3 pages)
Confirmation statement made on 2024-11-30 with no updates
- 18/10/2024View PDF (1 pages)
Termination of appointment of Bo Liang as a director on 2024-10-18
- 18/10/2024View PDF (2 pages)
Appointment of Ka King Cheng as a director on 2024-10-18
- 05/09/2024View PDF (23 pages)
Full accounts made up to 2022-12-31
- 22/03/2024View PDF (20 pages)
Full accounts made up to 2021-12-31
- 14/12/2023View PDF (2 pages)
Notification of Bo Liang as a person with significant control on 2023-06-21
- 14/12/2023View PDF (3 pages)
Confirmation statement made on 2023-11-30 with no updates
- 26/09/2023View PDF (1 pages)
Compulsory strike-off action has been discontinued
- 18/09/2023View PDF (1 pages)
Termination of appointment of Ka King Cheng as a director on 2023-06-21
- 18/09/2023View PDF (1 pages)
Termination of appointment of Bradley Peter Lancken as a director on 2023-06-21
Showing 12 of 20 filings
See when the next accounts and confirmation statement are due
Similar companies
1 UK company is similar to GENEA BIOMEDX UK LIMITED, sharing the same company status (Active), the same industry sector and activity group (Other research and experimental development on natural sciences and engineering) and a comparable number of employees. It is shown below to help you compare competitors and industry peers.
DUNAD THERAPEUTICS LTD.
ActiveThe Officers' Mess, Royston Road, Cambridge CB22 4QH
- Activity
- Research and experimental development on biotechnology
- Company no.
- 12544797
- Incorporated
- 02/04/2020
- Employees
- 7
About GENEA BIOMEDX UK LIMITED
A short description of the company, written from its Companies House record.
GENEA BIOMEDX UK LIMITED is a private limited company registered in the United Kingdom, based in Office 20 Second Floor Innovation House, Ramsgate Road, Sandwich, Kent CT13 9FF. Companies House classifies its business as Other research and experimental development on natural sciences and engineering. It has been on the register for 13 years 9 months.
The register currently records it as active. Its 2023 accounts report net assets of £-6.22M and 5 employees. Its accounts are past the filing deadline shown on the registry record.
GENEA BIOMEDX UK LIMITED: frequently asked questions
Answered from this company's own registry record and filed figures.
What does GENEA BIOMEDX UK LIMITED do?
Companies House records GENEA BIOMEDX UK LIMITED under one registered business activity: Other research and experimental development on natural sciences and engineering (72.19 - SIC 2007).
Is GENEA BIOMEDX UK LIMITED still active?
GENEA BIOMEDX UK LIMITED is recorded as active on the Companies House register, and has been on it since 30/11/2012.
What are GENEA BIOMEDX UK LIMITED's latest reported financials?
The most recent accounts Okredo holds cover 2023 and report net assets of £-6.22M, total assets of £1.47M, cash in bank of £158.31K and total liabilities of £7.69M.
When did GENEA BIOMEDX UK LIMITED last file with Companies House?
The most recent document on the record is dated 19/01/2026: Full accounts made up to 2023-12-31, 8 months ago.
When are GENEA BIOMEDX UK LIMITED's next filings due?
On the current registry record, accounts are due by 30/09/2025, which has passed.
Who runs GENEA BIOMEDX UK LIMITED?
Companies House lists 10 officers (1 currently in post) and 6 people with significant control (2 current).